PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

• Status: Completed
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine extreme responders to second- and third-line Type 2 diabetes therapy using a prospective approach, and patients with slow or fast diabetes progression using a retrospective approach.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NIHR Exeter Clinical Research Facility; Royal Devon and Exeter NHS Foundation Trust
• Collaborators: King's College Hospital NHS Trust; King's College London; Newcastle University; Newcastle-upon-Tyne Hospitals NHS Trust; NHS Greater Glasgow and Clyde; Oxford University Hospitals NHS Trust; Royal Devon and Exeter NHS Foundation Trust; University of Exeter; University of Glasgow
• Treatments: Dipeptidyl-Peptidase IV Inhibitors; Sodium-Glucose Transporter 2 Inhibitors

Criteria

Inclusion Criteria:

• Demographics: Age 18-90 inclusive

• Ethnicity: Reflective of local demographic

• Medical History: Clinical diagnosis of Type 2 diabetes

• Mental Capacity: Capacity to Consent

Exclusion Criteria:

• Age less than 18 years old and greater than 90 years old

• Incapacity to consent

• Type 1 diabetes.